Efficacy of Retinalamin® in various ophthalmological diseases
https://doi.org/10.52485/19986173_2022_4_98
Abstract
Due to the high prevalence of the posterior eye segment diseases, the search for effective methods of their treatment is especially relevant. In recent years, neuroprotective therapy has been widely used, which is considered a promising direction due to a pathogenetically proven mechanism of action. The use of biogenic peptides in ophthalmology, including pediatric ophthalmology, makes it possible to activate the processes of reparation and intercellular interaction of retinal cells. The literature review presents data on the structure and pharmacological action of Retinalamin®, as well as the results of its use in various ophthalmic diseases.
About the Authors
I. V. Landa
Chita State Medical Academy
Russian Federation
Russian Federation
39a Gorky Street, Chita, 6720000
E. S. Taskina
Chita State Medical Academy
Russian Federation
Russian Federation
39a Gorky Street, Chita, 6720000
S. V. Kharintseva
Chita State Medical Academy
Russian Federation
Russian Federation
39a Gorky Street, Chita, 6720000
References
1. Li J.Q., Welchowski T., Schmid M., Mauschitz M.M., Holz F.G., Finger R.P. Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. Br J Ophthalmol. 2020. 104(8). 1077-1084. DOI: 10.1136/bjophthalmol-2019-314422.
2. Gallo Afflitto G., Aiello F., Cesareo M., Nucci C.J. Primary Open Angle Glaucoma Prevalence in Europe: A Systematic Review and Meta-Analysis. Glaucoma. 2022. 31(10). 783-788. DOI: 10.1097/IJG.0000000000002083.
3. Hansen M.H., Hvid-Hansen A., Jacobsen N., Kessel L. Myopia prevalence in Denmark – a review of 140 years of myopia research. Acta Ophthalmol. 2021. 99(2). 118-127. DOI: 10.1111/aos.14562.
4. Sacchetti M., Mantelli F., Merlo D., Lambiase A.J. Systematic Review of Randomized Clinical Trials on Safety and Efficacy of Pharmacological and Nonpharmacological Treatments for Retinitis Pigmentosa. Ophthalmol. 2015. 2015. 737053. DOI: 10.1155/2015/737053.
5. GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021. 9(2). 130-143. DOI: 10.1016/S2214-109X(20)30425-3.
6. Kuznik B.I., Morozov V.G., Khavinson V.Kh. Cytomedins (25 years of experience in experimental and clinical studies). St. Petersburg. The science. 1998. in Russian.
7. Khavinson V.Kh. Medicinal peptide preparations: past, present, future. Clinical medicine. 2020. 98(3). 165-177. in Russian. DOI: 10.30629/0023-2149-2020-98-3-165-177.
8. Egorov E. A., Erichev V. P., Strakhov V. V., Petrov S. Yu., Romanova T. B., Vasina M. V., Zinina V. S., Makarova A. S., Casanova S.Yu., Yartsev A.V. Structural and functional changes in the retina in patients with primary open-angle glaucoma with compensated intraocular pressure during retinoprotective therapy. Bulletin of ophthalmology. 2019. 135(3). 20-30. in Russian.
9. Saydasheva E.I. Neuroretinoprotection in pediatric ophthalmic practice. Russian pediatric ophthalmology. 2017. 12(4). 204-209. in Russian. DOI: 10.18821/1993-1859-2017-12-4-204-209.
10. Antonov A.A., Makarova A.S., Reshchikova V.S. Experimental studies of the effectiveness of Retinalamin. National Journal of Glaucoma. 2017. 16(3). 98-102. in Russian.
11. Isaikina N.V., Zapuskalov I.V., Krivosheina O.I. The possibility of using Retinalamine by epiretinal administration. Modern problems of science and education. 2015. 6. in Russian. [cited 15.11.2022]. Available from: https://science-education.ru/ru/article/view?id=23992.
12. Astakhov Yu.S., Butin E.V., Morozova N.V., Sokolov V.O., Florentseva S.S. Experience in the use of Retinalamin in the treatment of glaucoma neuroopticopathy and age-related macular degeneration. Ophthalmological records. 2013. 5(2). 45-49. in Russian.
13. Kharintseva S.V. Retinoprotective therapy for diabetic macular edema in the elderly. Advances in Gerontology. 2011. 24(3). 521-523. in Russian.
14. Strakhov V.V., Egorov E.A., Erichev V.P., Yartsev A.V., Petrov S.Yu., Dorofeev D.A. The effect of long-term retinoprotective therapy on the progression of glaucoma according to structural and functional studies. Bulletin of ophthalmology. 2020. 136(5). 58-66. in Russian. DOI: 10.17116/oftalma202013605158.
15. Egorov E.A., Egorov A.E., Brezhnev A.Yu. Neuroprotective therapy of glaucoma: guidelines. Moscow. April, 2012. 4-10. in Russian.
16. Egorov E.A., Egorova T.E., Shramko Yu.G. The effectiveness of Retinalamin in patients with compensated primary open-angle glaucoma. Clinical ophthalmology. 2014. 15(4). 188. in Russian.
17. Egorov E.A., Erichev V.P., Strakhov V.V., Petrov S.Yu., Romanova T.B., Vasina M.V., Zinina V.S., Makarova A.S., Casanova S.Yu., Yartsev A.V. Structural and functional changes in the retina in patients with primary open-angle glaucoma with compensated intraocular pressure during retinoprotective therapy. Bulletin of ophthalmology. 2019. 135(3). 20-30. in Russian. DOI: 10.17116/oftalma201913503120.
18. Alekseev V.N. Churilina N.Yu. Pavlova E.A. Morphometric substantiation of the neuroprotective effect of peptides in primary open-angle glaucoma. Successes of modern natural science. 2008. 2. 89-91. in Russian.
19. Fedotova T.S., Khokkanen V.M., Trofimova S.V., Dautova Z.A. A modern approach to the treatment of dry age-related macular degeneration. Medical Bulletin of Bashkortostan. 2014. 9(2). 141-144. in Russian.
20. Neroev V.V., Zaitseva O.V., Okhotsimskaya T.D., Tsapenko I.V., Lantukh E.P. Efficacy of Retinalamin in patients with dry form of age-related macular degeneration with different frequency rates of intramuscular injections. Russian ophthalmological journal. 2016. 9(1). 39-46. in Russian. DOI: 10.21516/2072-0076-2016-9-1-39-46.
21. Erichev V.P., Petrov S.Yu., Volzhanin A.V. Meta-analysis of clinical studies of the effectiveness of retinoprotective therapy for the "dry" form of AMD using the drug Retinalamin® on the dynamics of visual acuity of breast cancer. Clinical ophthalmology. 2017. 4. 219-225. in Russian. DOI: 10.18008/1816-5095-2018-1-69-79.
22. Egorov E.A. Experience in the use of Retinalamin in various ophthalmic diseases. breast cancer. Clinical ophthalmology. 2017. 35-38. in Russian. DOI: 10.21689/2311-7729-2017-17-1-35-38.
23. Zhalalova D.Z., Kosimov Zh., Mansurov Sh., Zhabborov Sh. Epidemiology, prevalence, risk factors and progression of diabetic reptinopathy. Science and innovation. 2022. 3. 356-36. in Russian. DOI: 10.5281/zenodo.6806147.
24. Kanyukova Yu.V. The results of panretinal laser coagulation in patients with diabetes mellitus in combination with the use of Retinalamine. Kuban Scientific Medical Bulletin. 2011. 1(124). 51- 54. in Russian.
25. Gabdrakhmanova A.F., Galliamova G.R., Aleksandrov A.A. The state of eye hemodynamics in diabetic retinopathy and ophthalmoneuroprotection. Medical Bulletin of Bashkortostan. 2014. 9(2). 110-114. in Russian.
26. Astakhov Yu.S., Belova T.V., Boiko E.V., Lukovskaya N.G., Ryabtseva A.A., Saigina E.A., Terekhova I.V., Fokina D.V. The effectiveness of Retinalamin in the complex treatment of rhegmatogenous retinal detachment. Ophthalmological records. 2016. 9(4). 69-77. in Russian. DOI: 10.17816/OV9469-77.
27. Alexandrova T.E., Alexandrov E.I. To the question of peptide bioregulators: does Retinalamin have a cataractostatic effect? Ophthalmological records. 2008. 1(4). 52-56. in Russian.
Review
For citations:
Landa I.V., Taskina E.S., Kharintseva S.V. Efficacy of Retinalamin® in various ophthalmological diseases. Transbaikalian Medical Bulletin. 2022;(4):98-106. (In Russ.) https://doi.org/10.52485/19986173_2022_4_98
Views:
127
Email this article 